Effects of ertugliflozin on uric acid and gout‐related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from <scp>VERTIS CV</scp>
Vikas S. Sridhar(University Health Network), David Z.I. Cherney(University Health Network), Margaret Noyes Essex(Pfizer (United States)), Nilo B. Cater(Pfizer (United States)), Francesco Cosentino, Darren K. McGuire(Parkland Health & Hospital System), Yujie Zhao(Merck & Co., Inc., Rahway, NJ, USA (United States)), Richard E. Pratley(Translational Research Institute for Metabolism and Diabetes), James P. Mancuso(Pfizer (United States)), Samuel Dagogo‐Jack(University of Tennessee Health Science Center)
Cited by 8
Related Papers
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
|The Lancet|2018|1.8k
2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes
|European Heart Journal|2023|1.4k